目次

TABLE OF CONTENTS

1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.7 RECESSION IMPACT

2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
2.3 RESEARCH METHODOLOGY DESIGN
2.4 MARKET SIZE ESTIMATION
2.5 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6 RESEARCH ASSUMPTIONS
2.7 RISK ASSESSMENT
2.8 RESEARCH LIMITATIONS
2.8.1 METHODOLOGY-RELATED LIMITATIONS
2.8.2 SCOPE-RELATED LIMITATIONS
2.9 RECESSION IMPACT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW
5.1 MARKET DYNAMICS
5.1.1 DRIVERS
5.1.2 RESTRAINTS
5.1.3 OPPORTUNITIES
5.1.4 CHALLENGES
5.2 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.3 INDUSTRY TRENDS
5.4 ECOSYSTEM ANALYSIS
5.5 VALUE CHAIN ANALYSIS
5.6 TECHNOLOGY ANALYSIS
5.7 TARIFF AND REGULATORY LANDSCAPE
5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.7.2 REGULATORY ANALYSIS
5.7.2.1 North America
5.7.2.1.1 US
5.7.2.1.2 Canada
5.7.2.2 Europe
5.7.2.3 Asia Pacific
5.7.2.3.1 Japan
5.7.2.3.2 China
5.7.2.3.3 India
5.7.2.4 Latin America
5.8 PRICING ANALYSIS
5.8.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY SOFTWARE
5.8.2 AVERAGE SELLING PRICE TREND, BY REGION
5.9 PORTER’S FIVE FORCES ANALYSIS
5.10 PATENT ANALYSIS
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.11.2 BUYING CRITERIA
5.12 END USER ANALYSIS
5.12.1 UNMET NEEDS
5.12.2 END USER EXPECTATIONS
5.13 KEY CONFERENCES & EVENTS IN 2023-2024
5.14 RADIATION DOSE MANAGEMENT INVESTMENT LANDSCAPE
5.15 RADIATION DOSE MANAGEMENT BUSINESS MODELS
5.16 USE CASES/CASE STUDIES

6 RADIATION DOSE MANAGEMENT MARKET, BY PRODUCT & SERVICE
6.1 INTRODUCTION
6.2 RADIATION DOSE MANAGEMENT SOLUTIONS
6.2.1 STANDALONE SOLUTIONS
6.2.2 INTEGRATED SOLUTIONS
6.3 RADIATION DOSE MANAGEMENT SERVICES
6.3.1 SUPPORT & MAINTENANCE SERVICES
6.3.2 IMPLEMENTATION & INTERATION SERVICES
6.3.3 CONSULTING SERVICES
6.3.4 EDUCATION & TRAINING SERVICES

7 RADIATION DOSE MANAGEMENT MARKET, BY MODALITY
7.1 INTRODUCTION
7.2 COMPUTED TOMOGRAPHY
7.3 FLUOROSCOPY & INTERVENTIONAL IMAGING
7.4 RADIOLOGY
7.5 MAMMOGRAPHY
7.6 NUCLEAR MEDICINE

8 RADIATION DOSE MANAGEMENT MARKET, BY MODE OF DEPLOYMENT
8.1 INTRODUCTION
8.2 ON-PREMISE
8.3 CLOUD-BASED
8.4 WEB-BASED

9 RADIATION DOSE MANAGEMENT MARKET, BY REVENUE MODEL
9.1 CAPITAL/ANNUAL PURCHASE MODEL
9.2 PAY-PER PROCEDURE MODEL
9.3 OTHERS (IF ANY)

10 RADIATION DOSE MANAGEMENT MARKET, BY APPLICATION
10.1 INTRODUCTION
10.2 ONCOLOGY
10.3 CARDIOLOGY
10.4 DENTAL
10.5 ORTHOPEDIC APPLICATIONS
10.6 OTHER APPLICATION (NEUROIMAGING, GENITOURINARY IMAGING, ETC)

11 RADIATION DOSE MANAGEMENT MARKET, BY ENDUSER
11.1 INTRODUCTION
11.2 HOSPITALS AND HEALTHCARE SYSTEM
11.3 AMBULATORY SURGERY CENTER
11.3 DIAGNOSTIC AND IMAGING CENTER
11.4 OTHER END USERS (ACADEMIC RESEARCH INSTITUTION, PUBLIC AND PRIVATE RESEARCH LABORATORIES)

12 RADIATION DOSE MANAGEMENT MARKET, BY REGION
12.1 INTRODUCTION
12.2 NORTH AMERICA
12.2.1 US
12.2.2 CANADA
12.2.3 NORTH AMERICA: IMPACT OF ECONOMIC RECESSION
12.3 EUROPE
12.3.1 GERMANY
12.3.2 FRANCE
12.3.3 UK
12.3.4 ITALY
12.3.5 SPAIN
12.3.6 REST OF EUROPE
12.3.7 EUROPE: IMPACT OF ECONOMIC RECESSION
12.4 ASIA PACIFIC
12.4.1 CHINA
12.4.2 JAPAN
12.4.3 INDIA
12.4.3 REST OF ASIA PACIFIC
12.4.5 ASIA PACIFIC: IMPACT OF ECONOMIC RECESSION
12.5 LATIN AMERICA
12.5.1 BRAZIL
12.5.2 MEXICO
12.5.3 REST OF LATIN AMERICA
12.5.4 LATIN AMERICA: IMPACT OF ECONOMIC RECESSION
12.6 MIDDLE EAST AND AFRICA
12.6.1 GCC COUNTRIES
12.6.2 REST OF MIDDLE EAST & AFRICA
12.6.3 MIDDLE EAST & AFRICA: IMPACT OF ECONOMIC RECESSION

13 COMPETITIVE LANDSCAPE
13.1 OVERVIEW
13.2 STRATEGIES ADOPTED BY KEY PLAYERS
13.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
13.4 MARKET SHARE/RANKING ANALYSIS
13.5 BRAND/SOFTWARE COMPARATIVE ANALYSIS
13.6 VALUATION AND FINANCIAL METRICS OF KEY RADIATION DOSE MANAGEMENT VENDORS
13.7 COMPANY EVALUATION MATRIX
13.7.1 STARS
13.7.2 EMERGING LEADERS
13.7.3 PERVASIVE PLAYERS
13.7.4 PARTICIPANTS
13.7.5 COMPANY FOOTPRINT
13.8 START- UP/SME EVALUATION MATRIX
13.8.1 PROGRESSIVE COMPANIES
13.8.2 RESPONSIVE COMPANIES
13.8.3 DYNAMIC COMPANIES
13.8.4 STARTING BLOCKS
13.8.5 COMPETITIVE BENCHMARKING
13.9 COMPETITIVE SCENARIO AND TRENDS
13.9.1 PRODUCT LAUNCHES
13.9.2 DEALS
13.9.3 OTHERS

14 COMPANY PROFILES
14.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) *
14.1.1 BAYER AG
14.1.2 GE HEALTHCARE
14.1.3 PHILIPS HEALTHCARE
14.1.4 SECTRA AB
14.1.5 AGFA HEALTHCARE
14.1.6 SIEMENS HEALTHCARE
14.1.7 FUJIFILM HOLDINGS CORPORATION
14.1.8 CANON, INC.
14.1.9 GUERBET
14.1.10 PACSHEALTH
14.1.11 NOVARAD CORPORATION
14.1.12 QAELUM
14.1.13 BRACCO
14.1.14 INFINITT HEALTHCARE
14.1.15 MEDSQUARE SAS
14.2 OTHER KEY PLAYERS
14.2.1 VOLPARA HEALTH LIMITED.
14.2.2 MEDIC VISION
14.2.3 IMALOGIX.
14.2.4 DEDALUS S.P.A.
14.2.5 NANJING PERLOVE MEDICAL EQUIPMENT CO., LTD.
14.2.6 MIRION TECHNOLOGIES, INC.
14.2.7 LANDAUER
14.2.8 CENTRONIC
14.2.9 POLIMASTER
14.2.10 FORTIVE
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

15 APPENDIX
15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
15.3 AVAILABLE CUSTOMIZATIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS